By transferring miR-1228-3p to HCC cells, EVs produced from cancer-associated fibroblasts (CAFs) increased patient resistance to sorafenib by enhancing HCC invasion, migration, and proliferation through the activation of the PLAC8-mediated PI3K/AKT pathway [161]. Here, AKT1 is linked to hepatocellular carcinoma.